Arginine

Arginine

SCHEMBL5662952

COC(Cc1ccc(NCc2ccc3cc(OS(C)(=O)=O)ccc3c2)cc1)C(=O)O.N=C(N)NCCC[C@H](N)C(=O)O

nearest known ligand 0.38

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACE

The experimentally established mechanism targets of Arginine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
PPARG P37231 7/20 0.38
PPARA Q07869 6/20 0.37
NPY4R P50391 7/20 0.35
NPY1R P25929 4/20 0.35
SLC2A1 P11166 1/20 0.35
PPARD Q03181 3/20 0.34
ITGB3 P05106 1/20 0.34
ITGA2B P08514 1/20 0.34
FFAR1 O14842 2/20 0.34
NPY2R P49146 2/20 0.33
NPY5R Q15761 2/20 0.33
TPH1 P17752 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Arginine SCHEMBL5658957 1.00 PPARG (0.38) PPARGPPARANPY4RNPY1RSLC2A1
Arginine SCHEMBL4081908 0.87 PPARG (0.51) PPARGPPARAPPARD
Arginine SCHEMBL4081910 0.87 PPARG (0.51) PPARGPPARAPPARD
Arginine SCHEMBL5662160 0.85 MTNR1A (0.36) PPARGPPARANPY4RNPY1RPPARD
SCHEMBL5660930 0.85 PPARG (0.49) PPARGPPARASLC2A1PPARDFFAR1
SCHEMBL5659509 0.85 PPARG (0.49) PPARGPPARASLC2A1PPARDFFAR1
Arginine SCHEMBL4073126 0.85 MTNR1A (0.38) PPARGPPARANPY4RNPY1RPPARD
Arginine SCHEMBL4073128 0.85 MTNR1A (0.38) PPARGPPARANPY4RNPY1RPPARD
Arginine SCHEMBL4085067 0.85 MTNR1A (0.38) PPARGPPARANPY4RNPY1RPPARD
Arginine SCHEMBL4073283 0.81 PPARA (0.53) PPARGPPARAPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070093476-A1 Novel compounds and their use in medicine,as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them DR. REDDY'S LABORATORIES LIMITED (IN) 2007-04-26 US claimed
EP-1680397-A2 NOVEL COMPOUNDS AND THEIR USE AS ANTIDIABETIC AND HYPOLIPIDEMIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Dr. Reddy's Laboratories Ltd. (IN) 2006-07-19 EP disclosed
WO-2005040102-A2 NOVEL COMPOUNDS AND THEIR USE AS ANTIDIABETIC AND HYPOLIPIDEMIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DR. REDDY'S LABORATORIES LTD. (IN) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070093476-A1 Novel compounds and their use in medicine,as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them GPR119, NR1H3, NR1H2 PPARG 170/4885PPARA 251/4885NPY4R 26/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.